Savara (NASDAQ:SVRA) Trading Up 4.1% - Should You Buy?

Savara Inc (NASDAQ:SVRA - Get Free Report)'s share price traded up 4.1% on Tuesday . The stock traded as high as $3.05 and last traded at $3.02. 101,330 shares changed hands during trading, a decline of 92% from the average session volume of 1,328,423 shares. The stock had previously closed at $2.90.

Analyst Ratings Changes

Several research analysts recently issued reports on SVRA shares. Wells Fargo & Company initiated coverage on shares of Savara in a research report on Friday, December 20th. They issued an "overweight" rating and a $8.00 price target for the company. HC Wainwright reiterated a "buy" rating and set a $6.00 price objective on shares of Savara in a research note on Friday, March 28th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $8.83.

Savara Trading Up 2.7 %

The company has a market cap of $519.63 million, a price-to-earnings ratio of -7.00 and a beta of 0.52. The company has a debt-to-equity ratio of 0.13, a current ratio of 17.70 and a quick ratio of 17.70. The business has a 50 day simple moving average of $2.74 and a 200 day simple moving average of $3.10.

Savara (NASDAQ:SVRA - Get Free Report) last posted its quarterly earnings data on Thursday, March 27th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.02). The business had revenue of $0.27 million for the quarter. As a group, equities analysts forecast that Savara Inc will post -0.45 EPS for the current year.

Institutional Investors Weigh In On Savara

Hedge funds and other institutional investors have recently made changes to their positions in the company. Vestal Point Capital LP increased its position in Savara by 33.2% in the fourth quarter. Vestal Point Capital LP now owns 10,775,000 shares of the company's stock worth $33,079,000 after purchasing an additional 2,685,000 shares during the period. Frazier Life Sciences Management L.P. lifted its holdings in Savara by 6.2% in the fourth quarter. Frazier Life Sciences Management L.P. now owns 8,660,379 shares of the company's stock valued at $26,587,000 after buying an additional 502,994 shares during the period. Vanguard Group Inc. boosted its stake in Savara by 4.6% in the fourth quarter. Vanguard Group Inc. now owns 8,309,970 shares of the company's stock valued at $25,512,000 after acquiring an additional 365,959 shares during the last quarter. Deerfield Management Company L.P. Series C grew its holdings in Savara by 23.2% during the 4th quarter. Deerfield Management Company L.P. Series C now owns 7,964,000 shares of the company's stock worth $24,449,000 after acquiring an additional 1,498,223 shares during the period. Finally, Nantahala Capital Management LLC raised its position in shares of Savara by 45.2% during the 4th quarter. Nantahala Capital Management LLC now owns 7,525,259 shares of the company's stock valued at $23,103,000 after acquiring an additional 2,344,308 shares during the last quarter. 87.93% of the stock is owned by institutional investors and hedge funds.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.